Renal cell carcinoma (RCC) is mainly comprised of clear cell, papillary, and chromophobe subtypes. The study of hereditary kidney cancer syndromes has led to the identification of kidney cancer-related genes that are also involved in sporadic RCC. Recently, germline *BHD* mutations were found in patients with Birt--Hogg--Dubé (BHD) syndrome ([Nickerson *et al*, 2002](#bib8){ref-type="other"}), and a diverse spectrum of renal tumours have been described with somatic inactivation of *BHD* reported in BHD-related renal tumours ([Khoo *et al*, 2002](#bib6){ref-type="other"}; [Schmidt *et al*, 2005](#bib11){ref-type="other"}; [Vocke *et al*, 2005](#bib13){ref-type="other"}). *BHD* promoter methylation has been reported in a subset of sporadic clear cell and chromophobe RCC, but somatic mutation of *BHD* in sporadic cases is rare ([da Silva *et al*, 2003](#bib3){ref-type="other"}; [Khoo *et al*, 2003](#bib7){ref-type="other"}). *BHD* is located at 17p11.2, and LOH has been detected in all RCC subtypes ([Khoo *et al*, 2003](#bib7){ref-type="other"}; [Vocke *et al*, 2005](#bib13){ref-type="other"}). The *TP53* gene is located at 17p13.1 near *BHD*. A study has reported 30% of somatic missense mutations of *TP53* in chromophobe with LOH of chromosome 17p, suggesting that *TP53* plays a role in this subtype ([Contractor *et al*, 1997](#bib2){ref-type="other"}). The *HNF1β* gene (hepatocyte nuclear factor), which was found mutated in patients with maturity-onset diabetes of the young (MODY5), is located at 17q12 ([Horikawa *et al*, 1997](#bib5){ref-type="other"}). Biallelic inactivation of this gene has been reported in two of 12 patients with chromophobe RCC; both patients have germline *HNF1β* mutations, and their tumours showed LOH, suggesting inactivation through the classic two-hit hypothesis ([Rebouissou *et al*, 2005](#bib10){ref-type="other"}).

Multiple losses of whole chromosomes were frequently found in chromophobe RCC, especially in chromosome 17 ([Speicher *et al*, 1994](#bib12){ref-type="other"}). We hypothesised that the lost chromosomal regions may harbour chromophobe RCC-specific tumour suppressor genes, and their inactivation contributes to the tumorigenesis. Here, we focused on three cancer-related genes located at chromosome 17, *BHD*, *TP53*, and *HNF1β*, and examined their involvement in chromophobe RCC by studying 46 cases and compared with 19 clear cell, 18 oncocytoma, and nine papillary subtypes. We screened these tumours for mutations, evaluated the *BHD* promoter methylation status, and estimated the allelic frequencies of polymorphisms in these genes.

MATERIALS AND METHODS
=====================

Tissue samples and DNA extraction
---------------------------------

Ninety-two frozen sporadic renal tumour samples were collected from various hospitals in France and USA (French Kidney Tumour Consortium and Cooperative Human Tissue Network). All patients are of Caucasian origin. This included two patients with bilateral chromophobe RCC but without evidence of genetic predisposition. This study was performed after approval from our local Ethics Committee. Informed consent was obtained from each patient. Genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Courtaboeuf, France) according to the manufacturer\'s instructions.

Sequencing analysis
-------------------

The entire coding region of *BHD*, *TP53*, and *HNF1β* was screened for mutations by direct sequencing ([Nickerson *et al*, 2002](#bib8){ref-type="other"}; B. Bressac-de Paillerets, unpublished data; [Rebouissou *et al*, 2005](#bib10){ref-type="other"}; see [Supplementary Information](#sup1){ref-type="other"}).

SNP analysis
------------

Intronic and exonic SNPs (iSNPs and eSNPs) were obtained from the sequencing results. Rare homozygous genotypes have the lowest allelic frequencies according to the Hardy--Weinberg\'s law. We used the allelic frequencies of HapMap--CEU (<http://www.hapmap.org>).

Methylation analysis of the *BHD* promoter region
-------------------------------------------------

Genomic DNA were incubated with or without *Hpa*II (Invitrogen, Cergy-Pontoise, France). Polymerase chain reaction (PCR) was then performed with specific primers (available on request) and products were analysed on standard agarose gels. The presence of methylated cytosines was determined by comparing the same sample under the digested or nondigested conditions, that is, if cytosines were methylated, *Hpa*II would not be cleaved at the restriction enzyme sites, and PCR amplification would be successful.

Statistical analysis
--------------------

*χ*^2^ test was used to compare the mutation frequencies as well as the frequencies of rare homozygous genotypes of each polymorphism in each tumour subtype. When the conditions of application of *χ*^2^ could not be obtained, a Yates\'s correction was applied, or the Fisher\'s exact test was used. Statistical significance was indicated by *P*\<0.05.

RESULTS AND DISCUSSION
======================

Alterations in *BHD*
--------------------

Two nonsense, three frameshift, and three predicted splice mutations were identified in six samples, five of 46 chromophobe RCC (10.9%) and one of 18 oncocytomas (5.6%) ([Table 1](#tbl1){ref-type="table"}). This is the first report of somatic *BHD* mutations in sporadic chromophobe RCC and renal oncocytoma. T16 and T35 exhibited their respective mutations in both tumour and corresponding matched normal tissue, showing possible germline mutations, although contamination of tumour cells in the normal tissue could not be ruled out completely. Unfortunately, the blood DNA of these patients could not be obtained to verify their germline mutation status. T16 also showed loss of the wild-type allele but retained mutant strand in its tumour tissue (LOH) ([Figure 1A](#fig1){ref-type="fig"}). Two chromophobe RCC (T68 and T87b) showed a double mutation in each of the tumours. In patient A (T87a and T87b), we detected two novel somatic mutations and a previously described germline alteration ([Schmidt *et al*, 2005](#bib11){ref-type="other"}), which was confirmed with the patient\'s blood DNA. Although patient A did not show any evidence of genetic predisposition, he has bilateral chromophobe RCC, and a germline mutation makes him a potential hereditary case and was referred to genetic counsellors. T68 showed two distinct somatic mutations not found in the matched normal tissues. The second somatic mutation is a possible second hit, instead of LOH, further supporting the tumour suppressive role of *BHD*. We did not detect any mutation at the hot spot within exon 11 as reported in BHD patients. The *BHD* mutation frequency in chromophobe is statistically not significant compared to the other subtypes (*P*\>0.20, with Yates\'s correction). Methylation status of the *BHD* promoter was analysed on 61 of 92 samples (39 chromophobe, seven clear cell, and 15 oncocytoma), which had sufficient DNA quantity to perform the enzymatic digestion. No evidence of *BHD* promoter methylation was found.

Mutations in *TP53*
-------------------

Eight missense, three frameshift, one in-frame, and one predicted splice mutations were identified in 13 tumours, 11 of 46 chromophobe (23.9%), one of 19 clear cell (5.3%), and one of nine papillary RCC (11.1%). The mutation in T75 is located at the last base of exon 4 that can induce a splicing effect ([Holmila *et al*, 2003](#bib4){ref-type="other"}). A known hot spot mutation in sarcomatoid RCC ([Oda *et al*, 1995](#bib9){ref-type="other"}) has been detected in one papillary (T26) and one chromophobe (T63). A sarcomatoid component can occur in all subtypes, and its presence indicates poor outcome ([Cheville *et al*, 2004](#bib1){ref-type="other"}). The matched normal tissue of T9, a clear cell subtype, has the same mutation as its tumour tissue, suggesting a possible germline mutation ([Figure 1B](#fig1){ref-type="fig"}). However, no blood DNA was available to confirm its germline status. All *TP53* mutations detected here have been described in the *TP53* database (www-p53.iarc.fr/P53aim.html). The *TP53* mutation frequency in chromophobe is statistically significant compared to the other subtypes (*P*\<0.01). Therefore, *TP53* mutations occur preferentially in chromophobe as reported ([Contractor *et al*, 1997](#bib2){ref-type="other"}). The high percentage of *TP53* mutations in chromophobe could reflect the different pathways in its tumorigenesis, compared to other subtypes.

Analysis of *HNF1β*
-------------------

No mutations were identified in all coding exons of the *HNF1β* gene. However, an insertion of a cytosine in the intron 8 was detected ([Table 2](#tbl2){ref-type="table"}, and [Table 3 in Supplementary Information](#sup1){ref-type="other"}). This is a deletion/insertion polymorphism (DIP) that has been reported previously ([Horikawa *et al*, 1997](#bib5){ref-type="other"}). Here the frequency of its rare genotype (insC) in chromophobe is statistically significant compared to the other subtypes (*P*\<0.02). Furthermore, this variant was observed in a normal tissue sample, but was lost in the matched tumour through LOH ([Figure 1C](#fig1){ref-type="fig"}). We could not establish any relationship between *HNF1β* and sporadic RCC as we did not find any mutations, suggesting *HNF1β* mutation as a very rare genetic event in sporadic renal tumours.

Analysis of SNPs in *BHD*, *TP53*, and *HNF1β*
----------------------------------------------

We detected 14 SNPs, including one possible new iSNP in *BHD* ([Table 2](#tbl2){ref-type="table"} and [Supplementary Table 3](#sup1){ref-type="other"}). All tumours that carry the *BHD* mutations showed homozygosity in all four iSNPs. All except two *TP53-*mutated tumours (T26 and T45) demonstrated homozygous alleles in all four SNPs. In addition, the proportion of samples showing homozygous SNP alleles in *BHD*, *TP53*, and *HNF1β* are 41/92 (44.6%), 65/92 (70.6%), and 37/92 (40.2%), respectively. Chromophobe RCC exhibited the highest percentage of rare homozygous genotypes ([Table 2](#tbl2){ref-type="table"}). Among the 92 renal tumours, 24 samples are homozygous for all SNP studied (26%). Twenty-one of them are of chromophobe subtype (45.6% of all chromophobe; *P*\<0.001). One of them carries a *BHD* mutation and eight of them have *TP53* mutations (72.7% of *TP53*-mutated chromophobe; *P*\<0.02). The other three are of oncocytoma subtype (16.7% of all oncocytoma). Homozygous SNP alleles detected in this study may indicate chromosomal deletions. In samples with mutations, it may suggest LOH, which is consistent with the two-hit hypothesis. However, we also noticed the high frequency of homozygous SNP alleles especially in samples without *TP53* mutation (70%). Although it has been shown that p53 is functional in p53 wild-type RCC cells ([Warburton *et al*, 2005](#bib14){ref-type="other"}), the relationship between chromosomal 17 deletions and *TP53*, especially in sporadic chromophobe subtype, is worth further investigation.

In summary, *BHD* and *TP53* may play an important role as tumour suppressors in chromophobe RCC.
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![Sequence chromatograms for *BHD*, *TP53*, and *HNF1β*. R, N, and T are DNA from a commercially available reference, the normal tissue and its matched tumour tissue, respectively. (**A**) Corresponds to *BHD* with a somatic mutation (T68, c.1433(IVS12)-2A\>T) (left) and a possible germline mutation (T16, c.103_125(558_580)del23) (right). (**B**) Corresponds to *TP53* with a somatic mutation (T72, c.393_395delCAA) (left) and a possible germline mutation (T9, c.467G\>A) (right). (**C**) Corresponds to *HNF1β* with a cytosine insertion in intron 8 (left) and a SNP in the non-coding region of exon 9 (c.^\*^99C\>) (right).](6603492f1){#fig1}

###### 

Description of mutations detected in *BHD* and *TP53* genes in 92 sporadic renal tumours

  **Gene**   **Sample**   **Cell type**      **Exon**  **Mutation description**   **Mutation type**           **Mutated protein**   **Mutation origin**
  ---------- ------------ ----------------- ---------- -------------------------- --------------------------- --------------------- ---------------------
  *BHD*      T16          Chromophobe RCC       4      c.103_125(558_580)del23    Frameshift                  p.Asn35fs             Possible germline
             T35          Chromophobe RCC       9      c.919(1374)G\>T^a^         Nonsense                    p.Glu307X             Possible germline
             T87a         Chromophobe RCC       9      c.995_998(1450_1453)del4   Frameshift                  p.Leu332fs            Somatic
             T87b         Chromophobe RCC       9      c.1062(IVS9)+2T\>G         Predicted splice mutation   x                     Germline
             T87b         Chromophobe RCC       11     c.1179(1634)delC           Frameshift                  p.Thr393fs            Somatic
             T68          Chromophobe RCC       11     c.1177(IVS10)-6delCCT      Predicted splice mutation   x                     Somatic
             T68          Chromophobe RCC       13     c.1433(IVS12)-2A\>T        Predicted splice mutation   x                     Somatic
             T55          Oncocytoma            14     c.1659(2114)G\>A           Nonsense                    p.Trp553X             Somatic
                                                                                                                                     
  *TP53*     T70          Chromophobe RCC       4      c.150_157del8^b^           Frameshift                  p.Ile50fs             ND
             T75          Chromophobe RCC       4      c.375G\>A^c^               Predicted splice mutation   p.Thr125Thr           ND
             T72          Chromophobe RCC       5      c.393_395delCAA            In frame deletion           p.Asn131del           Somatic
             T41          Chromophobe RCC       5      c.469G\>T                  Missense                    p.Val157Phe           Somatic
             T66          Chromophobe RCC       6      c.569delC                  Frameshift                  p.Pro190fs            Somatic
             T34          Chromophobe RCC       6      c.644G\>T                  Missense                    p.Ser215Ile           Somatic
             T33          Chromophobe RCC       7      c.757A\>G                  Missense                    p.Thr253Ala           Somatic
             T43          Chromophobe RCC       8      c.817C\>T                  Missense                    p.Arg273Cys           Somatic
             T63          Chromophobe RCC       8      c.832C\>A                  Missense                    p.Pro278Thr           ND
             T45          Chromophobe RCC       8      c.877dupA                  Frameshift                  p.Gly293fs            ND
             T62          Chromophobe RCC       10     c.1009C\>T                 Missense                    p.Arg337Cys           ND
             T9           Clear cell RCC        5      c.467G\>A                  Missense                    p.Arg156His           Possible germline
             T26          Papillary RCC         8      c.832C\>A                  Missense                    p.Pro278Thr           Somatic

Abbreviations: BHD=Birt--Hogg--Dubé; ND=Not determined owing to the unavailability of matched normal tissue.

For *BHD,* c. corresponds to coding sequence relative to ATG in exon 4 (Genbank accession number [NM_144997](NM_144997)). Numbers in brackets are refering to the previous nomenclature used (Genbank accession number [AF517523](AF517523)).

For *TP53*, c. corresponds to coding sequence according to ATG in exon 2 (Genbank accession number [NM_000546](NM_000546)).

Not a silent mutation because it involves the last base of exon 4 and has been reported to be responsible for exon skipping.

###### 

Polymorphisms detected in *BHD,* *TP53*, and *HNF1β* genes in 92 sporadic renal tumours

                                                         **Proportion of rare homozygous genotypes (%)^c^**                      
  --------- ----------- ----------- -------------------- ---------------------------------------------------- ------ ----- ----- -----
  *BHD*     rs1736219   Intron 5    c.397-14C\>T         28.3                                                 17.4   4.3   4.3   2.2
            rs3744124   Intron 8    c.871+36G\>A         0                                                    0      0     0     0
            rs8065832   Intron 9    c.1062+6C\>T         29.3                                                 19.6   4.3   3.3   2.2
                        Intron 12   c.1433-38A\>G        15.2                                                 12     2.2   1.1   0
                                                                                                                                  
  *TP53*    rs1642785   Intron 2    c.74+38G\>C          16.3                                                 10.9   2.2   2.2   1.1
            rs1800370   exon 4      c.108G\>A, p.P36P    1.1                                                  1.1    0     0     0
            rs1042522   exon 4      c.215G\>C, p.R72P    14.1                                                 10.9   2.2   1.1   0
            rs1800372   exon 6      c.639A\>G, p.R213R   1.1                                                  1.1    0     0     0
                                                                                                                                  
  *HNF1β*   rs2107133   Intron 6    c.1339+27T\>C        4.3                                                  4.3    0     0     0
                        Intron 8    c.1653+47_48insC     7.6                                                  7.6    0     0     0
            rs3110641   Intron 8    c.1654-22C\>T        15.2                                                 12     0     2.2   1.1
            rs8068014   exon 9      c.^\*^47T\>G^b^      1.1                                                  0      0     0     1.1
            rs2229295   exon 9      c.^\*^99C\>A^b^      10.9                                                 7.6    0     2.2   1.1
            rs1800929   exon 9      c.^\*^100A\>G^b^     2.2                                                  0      0     1.1   1.1
            rs2689      exon 9      c.^\*^274A\>T^b^     27.2                                                 17.4   3.3   5.4   1.1

Abbreviations: BHD=Birt--Hogg--Dubé; HNF=hepatocyte nuclear factor; RCC=renal cell carcinoma.

SNP information was obtained from [www.ncbi.nlm.nih.gov/SNP/](http://www.ncbi.nlm.nih.gov/SNP/).

These 4 SNPs are located in exon 9 of *HNF1β* after the translation stop codon (Genbank accession number [NM_000458](NM_000458)).

Rare homozygous genotypes are defined as genotypes having the lowest allelic frequency q^2^ according to the Hardy--Weinberg law and genotypes given in [Table 3 (Supplementary Information on line)](#sup1){ref-type="other"}.
